

## Final - February 17, 2023

### MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 22-24, 2023

#### Wednesday, February 22, 2023

8:00	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP, Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30	<b>Mpox Vaccine</b> Introduction Epidemiology of mpox during 2022 outbreak in the United States JYNNEOS vaccine safety JYNNEOS vaccine effectiveness Mpox vaccine acceptability and uptake from cross-sectional surveys  Interim clinical considerations EtR: Use of JYNNEOS during mpox outbreaks	Dr. Pablo Sanchez (ACIP, WG Chair) Dr. Sascha Ellington (CDC/NCCDPHP) Dr. Jonathan Duffy (CDC/NCEZID) Dr. Anna Chard (CDC/NCIRD) Dr. Kevin P. Delaney (CDC/NCHHSTP)  Dr. Rosalind Carter (CDC/NCIRD) Dr. Agam Rao (CDC/NCEZID)
11:30	<b>Break</b>	
12:30	<b>Respiratory disease surge, Fall 2022, United States</b>	Dr. José R. Romero (CDC, Director NCIRD)
1:00	<b>Influenza Vaccine</b> Introduction U.S. Influenza activity update Preliminary 2022-23 influenza vaccine effectiveness: CDC networks  Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin	Dr. Keipp Talbot (ACIP, WG Chair) Dr. Lisa Grohskopf (CDC/NCIRD) Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark Tenforde (CDC/NCIRD) Dr. Huong McLean, Marshfield Clinic Research Institute
1:50	<b>Break</b>	
2:00	<b>Public Comment</b>	
2:30	<b><u>VOTES</u></b> <b>Mpox</b>	Dr. Agam Rao (CDC/NCEZID)
2:50	<b>Break</b>	
3:00	<b>Pneumococcal Vaccines</b> Introduction Epidemiology of pneumococcal disease among U.S. children Estimating the impact of higher-valency PCVs on pediatric outpatient ARI visits and antibiotic use PCV20 Phase 2/3 study results among children Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children Workgroup considerations	Dr. Katherine Poehling (ACIP, WG Chair) Mr. Ryan Gierke (CDC/NCIRD) Ms. Laura King (UC Berkeley)  Dr. Wendy Watson (Pfizer) Dr. Miwako Kobayashi (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD)
5:00	<b>Adjourn</b>	

#### Thursday, February 23, 2023

8:00	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP, Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10	<b>Agency Updates</b> <i>CDC, CMS, FDA, HRSA, IHS, ODP, NIH</i>	
8:30	<b>Meningococcal Vaccines</b> Introduction Epidemiology of meningococcal disease in the United States Pfizer pentavalent meningococcal vaccine Workgroup considerations	Dr. Kathy Poehling (ACIP, WG Chair) Ms. Amy Rubis (CDC/NCIRD) Dr. Jason Maguire (Pfizer) Dr. Sam Crowe (CDC/NCIRD)
9:30	<b>Polio Vaccine</b> Introduction Recommendations for Adult Polio Vaccination	Dr. Oliver Brooks (ACIP, WG Chair) Dr. Sarah Kidd (CDC/NCIRD)
10:00	<b>Break</b>	

## Final - February 17, 2023

<b>10:20</b>	<b>RSV Vaccines - Pediatric/Maternal</b>	
	Introduction	Dr. Sarah Long (ACIP, WG Chair)
	Cost effectiveness analysis for nirsevimab – CDC model	Dr. David Hutton (University of Michigan)
	Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model	Dr. Ismael Ortega Sanchez (CDC/NCIRD)
	Evidence to Recommendations framework for nirsevimab	Dr. Jefferson Jones (CDC/NCIRD)
	Clinical considerations for nirsevimab	Dr. Jefferson Jones (CDC/NCIRD)
	Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine	Dr. Iona Munjal (Pfizer)
	Workgroup considerations	Dr. Katherine Fleming-Dutra (CDC/NCIRD)
<b>12:20</b>	<b>Break</b>	
<b>1:20</b>	<b>RSV Vaccines - Adult</b>	
	Introduction	Dr. Camille Kotton (ACIP, WG Chair)
	Cost effectiveness of the GSK and Pfizer vaccines (main CDC model)	Dr. David Hutton (University of Michigan)
	Comparison of cost effectiveness results of the main CDC model and each manufacturer model (GSK & Pfizer)	Dr. Ismael Ortega Sanchez (CDC/NCIRD)
	EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer)	Dr. Michael Melgar (CDC/NCIRD)
	Vaccine policy questions (GSK & Pfizer)	Dr. Michael Melgar (CDC/NCIRD)
<b>3:05</b>	<b>Break</b>	
<b>3:25</b>	<b>Chikungunya Vaccine</b>	
	Introduction	Dr. Beth Bell (ACIP, WG Chair)
	Global epidemiology of chikungunya	Dr. Susan Hills (CDC/NCEZID)
	Chikungunya in U.S. travelers	Ms. Nicole Lindsey (CDC/NCEZID)
	Persistent arthralgia following chikungunya	Ms. Nicole Lindsey (CDC/NCEZID)
	Workgroup considerations	Ms. Nicole Lindsey (CDC/NCEZID)
<b>4:25</b>	<b>Dengue Vaccines</b>	
	Introduction	Dr. Wilbur Chen (ACIP, WG Chair)
	Takeda dengue vaccine (TAK-003) safety and efficacy	Dr. Shibidas Biswal (Takeda)
	Workgroup considerations	Dr. Gabriela Paz-Bailey (CDC/NCEZID)
<b>5:10</b>	<b>Varicella</b>	
	Public health impact of 25 years of varicella vaccination in the United States	Dr. Mona Marin (CDC/NCIRD)
<b>5:30</b>	<b>Adjourn</b>	
<b><u>Friday, February 24, 2023</u></b>		
<b>8:00</b>	<b>Welcome &amp; Introductions</b>	
		Dr. Grace Lee (ACIP, Chair)
		Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>8:10</b>	<b>COVID-19 Vaccines</b>	
	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	COVID-19 vaccine safety updates: CDC	Dr. Tom Shimabukuro (CDC/NCEZID)
	COVID-19 vaccine safety updates: FDA	Dr. Richard Forshee (FDA)
	VaST summary	Dr. Keipp Talbot (ACIP, VaST Co-Chair)
	WG interpretation and summary	Dr. Evelyn Twentyman (CDC/NCIRD)
<b>9:30</b>	<b>Break</b>	
<b>9:45</b>	Updates on COVID-19 hospitalizations: COVID-NET	Dr. Chris Taylor (CDC/NCIRD)
	Updates to COVID-19 vaccine effectiveness in the United States	Dr. Amadea Britton (CDC/NCIRD)
	Considerations for transitioning to bivalent primary series	Dr. Sara Oliver (CDC/NCIRD)
<b>11:30</b>	<b>Break</b>	
<b>11:45</b>	Benefit/risk for COVID-19 vaccines	Dr. Megan Wallace (CDC/NCIRD)
	COVID-19 vaccines: future directions	Dr. Sara Oliver (CDC/NCIRD)
<b>1:45</b>	<b>Adjourn</b>	

**Acronyms**

ARI	Acute respiratory illness
CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
PCV20	20-valent pneumococcal conjugate vaccine
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
VaST	COVID-19 Vaccine Safety Technical Work Group
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness